CNS Pharmaceuticals (CNSP) Common Equity (2018 - 2025)
CNS Pharmaceuticals' (CNSP) quarterly Common Equity came in at $4.5 million in Q4 2025, down 26.78% YoY from $6.2 million in Q4 2024, and down 54.36% on a QoQ basis from $9.9 million in Q3 2025.
CNS Pharmaceuticals (CNSP) Common Equity (2018 - 2025) Analysis & Trends
CNS Pharmaceuticals (CNSP) has 8 years of Common Equity data on file, last reported at $4.5 million in Q4 2025.
- Quarterly Common Equity fell 26.78% year-over-year to $4.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.5 million (down 26.78% YoY) and the FY2025 annual result came in at $4.5 million, down 26.78% from the prior year.
- Common Equity fell to $4.5 million in Q4 2025, from $9.9 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $14.0 million in Q1 2022 to a low of -$4.4 million in Q4 2023.
- A 5-year average of $5.9 million and a median of $6.9 million in 2022 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2024 — Common Equity plunged 274.93% — and 2025, when it jumped 405.69%.
- Tracing CNSP's Common Equity over 5 years: stood at $6.2 million in 2021, then jumped by 31.96% to $8.1 million in 2022, then slumped by 154.5% to -$4.4 million in 2023, then soared by 239.36% to $6.2 million in 2024, then declined by 26.78% to $4.5 million in 2025.
- The last three Common Equity figures came in at $4.5 million (Q4 2025), $9.9 million (Q3 2025), and $13.1 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | CNS Pharmaceuticals | 2.66 Mn | -4.54 Mn | - | 4.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4.52 Mn |
| Sep 30, 2025 | 9.91 Mn |
| Jun 30, 2025 | 13.12 Mn |
| Mar 31, 2025 | 10.97 Mn |
| Dec 31, 2024 | 6.18 Mn |
| Sep 30, 2024 | 3.35 Mn |
| Jun 30, 2024 | -4.29 Mn |
| Mar 31, 2024 | -4.43 Mn |
| Dec 31, 2023 | -4.43 Mn |
| Sep 30, 2023 | -1.74 Mn |
| Jun 30, 2023 | 2.45 Mn |
| Mar 31, 2023 | 3.49 Mn |
| Dec 31, 2022 | 8.13 Mn |
| Sep 30, 2022 | 7.57 Mn |
| Jun 30, 2022 | 10.70 Mn |
| Mar 31, 2022 | 13.98 Mn |
| Dec 31, 2021 | 6.16 Mn |
| Sep 30, 2021 | 9.10 Mn |
| Jun 30, 2021 | 12.41 Mn |
| Mar 31, 2021 | 11.24 Mn |